Janux Therapeutics

Filed a patent for "compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens" on Fri, July 14, 2023

Filed a patent for "compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens" on Fri, February 23, 2024

Filed a patent for "optimized antibodies targeting cd3 and uses thereof" on Fri, February 17, 2023

Filed a patent for "tumor activated antibodies targeting cd3 and uses thereof" on Wed, May 3, 2023

Filed a patent for "compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens" on Thu, August 1, 2024

Filed a patent for "antibodies targeting egfr and cd3 and uses thereof" on Thu, November 10, 2022

Filed a patent for "compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens" on Thu, November 2, 2023

Filed a patent for "modified antibodies" on Thu, August 31, 2023

Filed a patent for "antibodies targeting trop2 and cd3 and uses thereof" on Thu, March 21, 2024

Filed a patent for "optimized antibodies targeting trop2 and uses thereof" on Fri, February 17, 2023

Filed a patent for "antibodies targeting egfr and cd3 and uses thereof" on Mon, March 6, 2023

Filed a patent for "antibodies targeting psma and cd3 and uses thereof" on Thu, February 8, 2024

Filed a patent for "multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof" on Thu, December 21, 2023

Filed a patent for "antibodies targeting her2 and cd3 and uses thereof" on Thu, December 21, 2023

Filed a patent for "tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof" on Thu, November 9, 2023

Filed a patent for "tumor activated antibodies targeting trop2 and uses thereof" on Thu, November 9, 2023

Filed a patent for "compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens" on Thu, February 22, 2024

Filed a patent for "peptide compositions and methods for anti-cd3 binding domains" on Thu, February 8, 2024

Filed a patent for "half-life extending compositions and methods" on Thu, February 1, 2024

Filed a patent for "compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens" on Thu, February 1, 2024

Filed a patent for "antibodies targeting egfr and cd3 and uses thereof" on Mon, November 6, 2023

Filed a patent for "compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens" on Mon, April 4, 2022

Filed a patent for "compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens" on Mon, April 4, 2022

Filed a patent for "compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens" on Wed, May 4, 2022

Filed a patent for "tumor activated antibodies targeting trop2 and uses thereof" on Wed, May 4, 2022